KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024

FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy

Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology

Triple Threat: 50% of Women Delay or Skip Medical Care Due to Affordability, Access, and Negative Experiences

Women’s healthcare, Delayed medical care, Affordability issues, Access barriers, Negative healthcare experiences, Gender disparities in healthcare, Healthcare equity

The Post-Chevron Regulatory Landscape: Implications for the FDA and Healthcare Industry

Chevron deference, FDA, regulatory landscape, healthcare industry, Supreme Court ruling, Loper Bright Enterprises v. Raimondo, Corner Post, Inc. v. Board of Governors of the Federal Reserve System, Administrative Procedure Act (APA), judicial scrutiny, legal challenges, regulatory implications.

Embracing Agility: Critical for the Role of QARA Professional

QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.

Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million

Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services